News

Global chemical company Shaanxi Chuzhan officially debuted at the 2025 China International Import Expo. At this year's CIIE, with the theme of ...

Chinese enterprises are transitioning towards technology driven exports 1. Challenges and Opportunities Since February 2025, the US government has ...

Retatrutide, a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, is revolutionizing obesity and diabetes treatment. Meanwhile, ...

In the field of metabolic disease treatment, new multi-target drugs are gradually overcoming the limitations of traditional single-target therapies...

Tropicamide (torpidamine) is an artificially synthesized anticholinergic drug, and its chemical structure belongs to the derivative of the scopolam...

The introduction of tirzepatide injection has marked a significant milestone, particularly in the management of type 2 diabetes and obesity. This i...

The International Feline Care Organization (iCatCare) has launched the 2025 World Feline Congress, its annual flagship continuing education event. ...

CJC-1295 is an artificially synthesized peptide hormone, belonging to the analog of growth hormone-releasing hormone (GHRH). Since it was first inc...

Tirzepatide is a novel dual receptor agonist that achieves the dual goals of blood sugar regulation and weight management by simultaneously activat...

The field of regenerative medicine and metabolic health is rapidly evolving, driven by breakthroughs in peptide-based therapies. Among these, Motsc...

Tirzepatide is a novel GLP-1/GIP dual receptor agonist, mainly used for the treatment of type 2 diabetes and obesity. It regulates blood sugar thro...

Tropicamide is a synthetic anticholinergic drug widely used in ophthalmology to induce mydriasis (pupil dilation) and cycloplegia (temporary paraly...